Skip to main content
SpringerLink
Log in

Botulinum Toxin A: Practical Tips for Use in the Field of Aesthetic Medicine

  • Chapter
  • First Online:
Non-Surgical Rejuvenation of Asian Faces

  • 1463 Accesses

Abstract

The use of botulinum toxin A (BoNT-A) in aesthetic medicine has exponentially increased since its first applications in 1989. Aesthetic uses include wrinkle reduction in various facial regions, including lines on the glabella, forehead, periorbital region, and perioral region, platysmal bands and lines, and facial contouring. Various products are available internationally, depending on one’s geographical location. Although botulinum neurotoxin type A is the active component in most formulations, the other ingredients and excipients of these products vary. Due to the fast-growing market and lack of systematic education and training, many myths exist regarding the cosmetic use of BoNT-A. In this chapter, we provide practical science-based tips to help both novice and experienced clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535–49.

    Article  CAS  PubMed  Google Scholar 

  2. Boone B. Botulinum toxin in aesthetic medicine. In European handbook of dermatological treatments. Springer, p. 1089–1106. 2015.

    Google Scholar 

  3. Gadhia K, Walmsley AD. Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. Br Dent J. 2009;207(5):E9. discussion 216–7

    Article  CAS  PubMed  Google Scholar 

  4. Brin MF, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61(6):961-70.e1-11.

    Article  PubMed  Google Scholar 

  5. Kaltreider SA, et al. Cosmetic oculofacial applications of botulinum toxin: a report by the American Academy of Ophthalmology. Ophthalmology. 2005;112(6):1159–67.

    Article  PubMed  Google Scholar 

  6. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981–90.

    Article  CAS  PubMed  Google Scholar 

  7. Cavallini M, Cirillo P, Fundaro S. Safety of botulinum toxin A in aesthetic treatments. A systematic review of clinical studies, p. 40. 2014.

    Google Scholar 

  8. Lacy DB, et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5(10):898–902.

    Article  CAS  PubMed  Google Scholar 

  9. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol. 2000;7(8):693–9.

    Article  CAS  PubMed  Google Scholar 

  10. Pirazzini M, et al. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pirazzini M, et al. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta Biomembr. 2016;1858(3):467–74.

    Article  CAS  Google Scholar 

  12. Brunger AT, et al. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 2007;3(9):e113.

    Article  PubMed Central  Google Scholar 

  13. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980;212(1):16–21.

    CAS  PubMed  Google Scholar 

  15. Naumann M. Clinical comparison of botulinum neurotoxin effects at the neuromuscular junction and autonomic nerves: similarities and differences. Toxicon. 2015;93:S46.

    Article  Google Scholar 

  16. Rowe JA, et al. Introduction to the autonomic nervous system and autonomic pharmacology. Veterinary Pharmacology and Therapeutics. 2017.

    Google Scholar 

  17. Ozcan C, Ismi O. Botulinum toxin for rhinitis. Curr Allergy Asthma Rep. 2016;16(8):58.

    Article  PubMed  Google Scholar 

  18. Mauad BA, et al. Changes in lower dental arch dimensions and tooth alignment in young adults without orthodontic treatment. Dental Press J Orthod. 2015;20(3):64–8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. In WHO best practices for injections and related procedures toolkit. Geneva. 2010.

    Google Scholar 

  20. Cohen JL, Beer K, Toxins B. In: Goldberg DJ, editor. Facial rejuvenation: a total approach. Berlin: Springer; 2007. p. 79–103.

    Chapter  Google Scholar 

  21. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24(11):1179–80.

    Article  CAS  PubMed  Google Scholar 

  22. Jaspers G, Pijpe J, Jansma J. The use of botulinum toxin type A in cosmetic facial procedures. Int J Oral Maxillofac Surg. 2011;40(2):127–33.

    Article  CAS  PubMed  Google Scholar 

  23. Klein AW. Cosmetic therapy with botulinum toxin anecdotal memoirs. Dermatol Surg. 1996;22(9):757–9.

    Article  CAS  PubMed  Google Scholar 

  24. Trindade de Almeida AR, et al. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg. 2003;29(5):530–2.

    Article  PubMed  Google Scholar 

  25. Kazim NA, Black EH. Botox: shaken, not stirred. Ophthalmic Plast Reconstr Surg. 2008;24(1):10–2.

    Article  PubMed  Google Scholar 

  26. Shome D, et al. Botulinum toxin A: is it really that fragile a molecule? Dermatol Surg. 2010;36(Suppl 4):2106–10.

    Article  CAS  PubMed  Google Scholar 

  27. Trindade de Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: an updated literature review. Dermatol Surg. 2011;37(11):1553–65.

    Article  CAS  PubMed  Google Scholar 

  28. Carruthers J, Fagien S, Matarasso S. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Ophthalmic Plast Reconstr Surg. 2005;21(2):165.

    Article  Google Scholar 

  29. Carey WD. Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin. J Drugs Dermatol. 2014;13(6):735–8.

    CAS  PubMed  Google Scholar 

  30. Niamtu J III. Neurotoxin waste from drawing product through the vial stopper. J Clin Aesthet Dermatol. 2014;7(6):33.

    PubMed  PubMed Central  Google Scholar 

  31. Seo KK Botoxology. In Botulinum toxin for Asians. Springer. p. 1–28. 2017

    Google Scholar 

  32. Khanna R, Tikku T, Sharma V. Position and orientation of hyoid bone in class II division I subjects: a cephalometric study. J Indian Orthod Soc. 2011;45:212–8.

    Article  Google Scholar 

  33. Using XEOMIN® (incobotulinumtoxinA) – Step by Step Reconstitution and dilution instructions. 2017 [cited 2018 June]; Available from: http://www.xeomin.com/physicians/about-xeomin/reconstitution-storage/

  34. Hoffman JA, Hoffman RL. Tongue-thrust and deglutition: some anatomical, physiological, and neurological considerations. J Speech Hear Disord. 1965;30:105–20.

    Article  CAS  PubMed  Google Scholar 

  35. Liu A, et al. Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol. 2012;67(3):373–8.

    Article  CAS  PubMed  Google Scholar 

  36. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21.

    Article  CAS  PubMed  Google Scholar 

  37. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol. 2002;138(4):510–4.

    Article  CAS  PubMed  Google Scholar 

  38. Kwiat DM, Bersani TA, Bersani A. Increased patient comfort utilizing botulinum toxin type a reconstituted with preserved versus nonpreserved saline. Ophthalmic Plast Reconstr Surg. 2004;20(3):186–9.

    Article  PubMed  Google Scholar 

  39. Sarifakioglu N, Sarifakioglu E. Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesthet Plast Surg. 2005;29(2):113–5.

    Article  Google Scholar 

  40. Wilson L, Martin S. Benzyl alcohol as an alternative local anesthetic. Ann Emerg Med. 1999;33(5):495–9.

    Article  CAS  PubMed  Google Scholar 

  41. Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(6):1S–22S.

    Article  PubMed  Google Scholar 

  42. Dressler D, Saberi FA, Bigalke H. Botulinum toxin therapy: reduction of injection site pain by pH normalisation. J Neural Transm. 2016;123(5):527–31.

    Article  CAS  PubMed  Google Scholar 

  43. Kim A, Jung J, Pak A. Botulinum toxin type A reconstituted in lidocaine with epinephrine for facial rejuvenation: results of a participant satisfaction survey. Cutis. 2013;Suppl:13–8.

    Google Scholar 

  44. Goodman G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol Surg. 2003;29(5):533–8.

    PubMed  Google Scholar 

  45. Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study. In Mayo Clinic Proceedings. Elsevier. 2000

    Google Scholar 

  46. Haubner F. Simultaneous injection of lidocaine improves predictability of effect of botulinum toxin. Laryngo-Rhino-Otologie. 2009;88(12):764.

    CAS  PubMed  Google Scholar 

  47. Kenner JR. Hyaluronic acid filler and botulinum Neurotoxin delivered simultaneously in the same syringe for effective and convenient combination aesthetic rejuvenation therapy. J Drugs Dermatol. 2010;9(9):1135–8.

    PubMed  Google Scholar 

  48. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol. 2007;156(5):986–9.

    Article  CAS  PubMed  Google Scholar 

  49. Hantash BM, Gladstone HB. A pilot study on the effect of epinephrine on botulinum toxin treatment for periorbital rhytides. Dermatol Surg. 2007;33(4):461–8.

    CAS  PubMed  Google Scholar 

  50. Yen MT, Wall VK. Bupivacaine-induced myotoxicity and its effect on botulinum toxin paresis. Ann Plast Surg. 2008;60(1):6–9.

    Article  CAS  PubMed  Google Scholar 

  51. Moore P, Naumann M. Handbook of botulinum toxin treatment. Wiley-Blackwell; 2003.

    Google Scholar 

  52. Alam M, et al. Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation. J Am Acad Dermatol. 2006;55(2):272–5.

    Article  PubMed  Google Scholar 

  53. Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg. 2008;10(4):273–9.

    Article  PubMed  Google Scholar 

  54. Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthalmic Plast Reconstr Surg. 2007;23(6):433–8.

    Article  PubMed  Google Scholar 

  55. Hexsel DM, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29(5):523–9.

    PubMed  Google Scholar 

  56. Kane M, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol. 2010;9(1 Suppl):s7–22. quiz s23–5

    PubMed  Google Scholar 

  57. Lizarralde M, Gutierrez SH, Venegas A. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg. 2007;33(11):1328–33.

    CAS  PubMed  Google Scholar 

  58. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48(1):249–53.

    Article  CAS  PubMed  Google Scholar 

  59. Hexsel D, et al. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg. 2009;35(6):933–40.

    Article  CAS  PubMed  Google Scholar 

  60. Menon J, Murray A. Microbial growth in vials of Botulinum toxin following use in clinic. Eye (Lond). 2007;21(7):995–7.

    Article  CAS  Google Scholar 

  61. Parsa AA, Lye KD, Parsa FD. Reconstituted botulinum type A neurotoxin: clinical efficacy after long-term freezing before use. Aesthet Plast Surg. 2007;31(2):188–91. discussion 192-3

    Article  Google Scholar 

  62. Osaki T, et al. Absence of bacterial or fungal growth in vials of reconstituted botulinum toxin type A after storage. Aesthet Surg J. 2015;35(2):189–93.

    Article  PubMed  Google Scholar 

  63. Barrow EM, et al. Safety and efficacy of multiuse botulinum toxin vials for intralaryngeal injection. Laryngoscope. 2015;125(5):1149–54.

    Article  CAS  PubMed  Google Scholar 

  64. Haney B. Reconstitution and dosing of neurotoxins. In: Haney B, editor. Aesthetic procedures: nurse practitioner's guide to cosmetic dermatology. Cham: Springer International Publishing; 2020. p. 91–7.

    Chapter  Google Scholar 

  65. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr. 2004;43(1):69–74.

    Article  Google Scholar 

  67. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child. 1998;79(1):59–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22(1):137–40.

    Article  CAS  PubMed  Google Scholar 

  69. Sezgin B, et al. The Effect of microneedle thickness on pain during minimally invasive facial procedures: a clinical study. Aesthet Surg J. 2014;34(5):757–65.

    Article  PubMed  Google Scholar 

  70. Zelickson BR, et al. Finer needles reduce pain associated with injection of local anesthetic using a minimal insertion injection technique. Dermatol Surg. 2018;44(2):204–8.

    Article  CAS  PubMed  Google Scholar 

  71. Alam M, et al. Effect of needle size on pain perception in patients treated with botulinum toxin type A injections: a randomized clinical trial. JAMA Dermatol. 2015;151(11):1194–9.

    Article  PubMed  Google Scholar 

  72. TSK The Invisible Needle™. 2017 [cited 2018 June]; Available from: https://tsklab.nl/wp-content/uploads/TSK-Aesthetic-Brochure.pdf.

  73. Smith KC, et al. Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures. Dermatol Online J. 2004;10(2).

    Google Scholar 

  74. Bini G, et al. Analgesic effect of vibration and cooling on pain induced by intraneural electrical stimulation. Pain. 1984;18(3):239–48.

    Article  PubMed  Google Scholar 

  75. Friedman PM, et al. Comparative study of the efficacy of four topical anesthetics. Dermatol Surg. 1999;25(12):950–4.

    Article  CAS  PubMed  Google Scholar 

  76. Dong H, Kerl H, Cerroni L. EMLA cream-induced irritant contact dermatitis. J Cutan Pathol. 2002;29(3):190–2.

    Article  PubMed  Google Scholar 

  77. Timmermans MW, Bruynzeel DP, Rustemeyer T. Allergic contact dermatitis from EMLA cream: concomitant sensitization to both local anesthetics lidocaine and prilocaine. J Dtsch Dermatol Ges. 2009;7(3):237–8.

    PubMed  Google Scholar 

  78. Weiss RA, Lavin PT. Reduction of pain and anxiety prior to botulinum toxin injections with a new topical anesthetic method. Ophthalmic Plast Reconstr Surg. 2009;25(3):173–7.

    Article  PubMed  Google Scholar 

  79. Hogan M-E, Kikuta A, Taddio A. A systematic review of measures for reducing injection pain during adult immunization. Vaccine. 2010;28(6):1514–21.

    Article  PubMed  Google Scholar 

  80. Irkoren S, Ozkan HS, Karaca H. A clinical comparison of EMLA cream and ethyl chloride spray application for pain relief of forehead botulinum toxin injection. Ann Plast Surg. 2015;75(3):272–4.

    Article  CAS  PubMed  Google Scholar 

  81. Hallett M. Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them. Toxicon. 2015;107:64–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Poulain B, et al. Differences in the temperature dependencies of uptake of botulinum and tetanus toxins in Aplysia neurons. Neurosci Lett. 1992;139(2):289–92.

    Article  CAS  PubMed  Google Scholar 

  83. Pirazzini M, et al. Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons. Biochem Biophys Res Commun. 2013;430(1):38–42.

    Article  CAS  PubMed  Google Scholar 

  84. Sharma P, Czyz CN, Wulc AE. Investigating the efficacy of vibration anesthesia to reduce pain from cosmetic botulinum toxin injections. Aesthet Surg J. 2011;31(8):966–71.

    Article  PubMed  Google Scholar 

  85. Nanitsos E, et al. The effect of vibration on pain during local anaesthesia injections. Aust Dent J. 2009;54(2):94–100.

    Article  CAS  PubMed  Google Scholar 

  86. Cheng CM. Cosmetic use of botulinum toxin type A in the elderly. Clin Interv Aging. 2007;2(1):81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Stephan S, Wang TD. Botulinum toxin: clinical techniques, applications, and complications. Facial Plast Surg. 2011;27(06):529–39.

    Article  CAS  PubMed  Google Scholar 

  88. Carruthers J, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies—consensus recommendations. Plast Reconstr Surg. 2008;121(5 Suppl):5S–30S.

    Article  CAS  PubMed  Google Scholar 

  89. Sundaram H, et al. Global aesthetics consensus: botulinum toxin type A—evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plast Reconstr Surg. 2016;137(3):518.

    Article  PubMed Central  Google Scholar 

  90. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295.

    PubMed  PubMed Central  Google Scholar 

  91. Sadashivaiah AB, Mysore V. Biofilms: their role in dermal fillers. J Cutan Aesthet Surg. 2010;3(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Beer K, Avelar R. Relationship between delayed reactions to dermal fillers and biofilms: facts and considerations. Dermatol Surg. 2014;40(11):1175–9.

    Article  CAS  PubMed  Google Scholar 

  93. Rohrich RJ, et al. Soft-tissue filler complications: the important role of biofilms. Plast Reconstr Surg. 2010;125(4):1250–6.

    Article  CAS  PubMed  Google Scholar 

  94. Coté TR, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407–15.

    Article  PubMed  Google Scholar 

  95. Hebl JR, Horlocker TT. You’re not as clean as you think! The role of asepsis in reducing infectious complications related to regional anesthesia. Reg Anesth Pain Med. 2003;28(5):376–9.

    PubMed  Google Scholar 

  96. Delnooz CC, et al. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia. Eur J Neurol. 2014;21(12):1486–e98.

    Article  CAS  PubMed  Google Scholar 

  97. Gracies JM, et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90(1):9–16.e2.

    Article  PubMed  Google Scholar 

  98. Bakheit AMO. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf. 2006;1(3):271–9.

    Article  CAS  PubMed  Google Scholar 

  99. Childers MK. The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin. Phys Med Rehab Clin. 2003;14(4):781–92.

    Article  Google Scholar 

  100. Guzmán-Venegas RA, Araneda OF, Silvestre RA. Differences between motor point and innervation zone locations in the biceps brachii. An exploratory consideration for the treatment of spasticity with botulinum toxin. J Electromyogr Kinesiol. 2014;24(6):923–7.

    Article  PubMed  Google Scholar 

  101. Lapatki B, et al. Botulinum toxin has an increased effect when targeted toward the muscle’s endplate zone: a high-density surface EMG guided study. Clin Neurophysiol. 2011;122(8):1611–6.

    Article  CAS  PubMed  Google Scholar 

  102. Lim EC, Quek AM, Seet RC. Accurate targeting of botulinum toxin injections: how to and why. Parkinsonism Relat Disord. 2011;17:S34–9.

    Article  PubMed  Google Scholar 

  103. Hexsel D, et al. Botulinum toxin for facial wrinkles: history and future. Expert Rev Dermatol. 2007;2(4):417–26.

    Article  CAS  Google Scholar 

  104. Jost WH, Valerius K-P. Pictorial atlas of botulinum toxin injection: dosage, localization, application. Quintessence Books. 2008.

    Google Scholar 

  105. Truong D, et al. Manual of botulinum toxin therapy. Cambridge University Press. 2014.

    Google Scholar 

  106. Chin TY, et al. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005;25(3):286–91.

    Article  PubMed  Google Scholar 

  107. Picelli A, et al. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: manual needle placement and electrical stimulation guidance compared using ultrasonography. J Rehabil Med. 2012;44(5):450–2.

    Article  PubMed  Google Scholar 

  108. Schnitzler A, et al. Manual needle placement: accuracy of botulinum toxin A injections. Muscle Nerve. 2012;46(4):531–4.

    Article  PubMed  Google Scholar 

  109. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29(5):549–56.

    PubMed  Google Scholar 

  110. Klein AW, Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998;24(11):1184–6.

    Article  CAS  PubMed  Google Scholar 

  111. O’Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve. 1997;20(S6):176–80.

    Article  Google Scholar 

  112. Dogu O, et al. Ultrasound-guided versus ‘blind’intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2004;106(2):93–6.

    Article  PubMed  Google Scholar 

  113. Westhoff B, et al. Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle. Dev Med Child Neurol. 2003;45(12):829–32.

    Article  PubMed  Google Scholar 

  114. Mantell AM. Dilution, storage, and electromyographic guidance in the use of botulinum toxins. Dermatol Clin. 2004;22(2):135–6. v

    Article  CAS  PubMed  Google Scholar 

  115. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141–50.

    Article  PubMed  Google Scholar 

  116. Gracies J-M, et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehab. 2009;90(1):9–16.e2.

    Article  Google Scholar 

  117. Carruthers A, et al. A randomized, evaluator-blinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type A in the treatment of lateral orbital rhytides. Dermatol Surg. 2007;33(5):567–71.

    CAS  PubMed  Google Scholar 

  118. Carruthers A, Carruthers J, Cohen J. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? Dermatol Surg. 2007;33(1 Spec No.):S97–104.

    Google Scholar 

  119. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol. 2004;140(11):1351–4.

    Article  CAS  PubMed  Google Scholar 

  120. Abbasi NR, et al. A small study of the relationship between abobotulinum toxin a concentration and forehead wrinkle reduction. Arch Dermatol. 2012;148(1):119–21.

    Article  PubMed  Google Scholar 

  121. Punga AR, et al. A randomized, comparative study to evaluate efficacy and safety of two injection volumes of AbobotulinumtoxinA in treatment of glabellar lines. Dermatol Surg. 2016;42(8):967–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Carruthers JA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840–9.

    Article  PubMed  Google Scholar 

  123. Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol. 2000;43(1):13–6.

    Article  CAS  PubMed  Google Scholar 

  124. Feng Z, et al. Optimal dosage of botulinum toxin type A for treatment of glabellar frown lines: efficacy and safety in a clinical trial. Dermatol Surg. 2015;41:S56–63.

    Article  CAS  PubMed  Google Scholar 

  125. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31(4):414–22.

    Article  CAS  PubMed  Google Scholar 

  126. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  127. Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines. 2018.

    Google Scholar 

  128. Poewe W, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®. J Neurol Neurosurg Psychiatry. 1998;64(1):13–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins. 2019;11(9):491.

    Article  CAS  PubMed Central  Google Scholar 

  130. Naumann M, et al. Immunogenicity of botulinum toxins. J Neural Transm (Vienna, Austria: 1996). 2013;120(2):275–90.

    Article  CAS  Google Scholar 

  131. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S92–s100.

    Article  PubMed  Google Scholar 

  132. Jinnah HA, et al. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol. 2016;263(6):1188–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Borodic G. Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthalmic Plast Reconstr Surg. 2006;22(3):239–40.

    Article  PubMed  Google Scholar 

  134. Dressler D, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg. 2010;36(Suppl 4):2182–7.

    Article  CAS  PubMed  Google Scholar 

  135. Stengel G, Bee EK. Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. Clin Interv Aging. 2011;6:281–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Torres S, et al. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11–7.

    PubMed  Google Scholar 

  137. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R&D. 2015;15(1):1–9.

    Article  CAS  Google Scholar 

  138. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743–6.

    Article  CAS  PubMed  Google Scholar 

  139. Atassi MZ, et al. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45(15):3878–88.

    Article  CAS  PubMed  Google Scholar 

  140. Dressler D, Saberi FA. Safety of botulinum toxin short interval therapy using incobotulinumtoxin A. J Neural Transm (Vienna). 2017;124(4):437–40.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. King’s College London, London, UK

    Souphiyeh Samizadeh

  2. University College London, London, UK

    Souphiyeh Samizadeh & Rajiv Grover

  3. Great British Academy of Aesthetic Medicine, London, UK

    Souphiyeh Samizadeh

Authors
  1. Souphiyeh Samizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajiv Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Souphiyeh Samizadeh .

Editor information

Editors and Affiliations

  1. Craniofacial Sciences, Centre for Craniofacial and Regenerative Biology, King’s College London, London, UK

    Souphiyeh Samizadeh

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Samizadeh, S., Grover, R. (2022). Botulinum Toxin A: Practical Tips for Use in the Field of Aesthetic Medicine. In: Samizadeh, S. (eds) Non-Surgical Rejuvenation of Asian Faces. Springer, Cham. https://doi.org/10.1007/978-3-030-84099-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84099-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84098-3

  • Online ISBN: 978-3-030-84099-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation